FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

por Tillman, Erik J., Rolph, Tim
Publicado 2020

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

por Tillman, Erik J., Brock, William J., Rolph, Tim
Publicado 2022

Three Months of High-Fructose Feeding Fails to Induce Excessive Weight Gain or Leptin Resistance in Mice

por Tillman, Erik J., Morgan, Donald A., Rahmouni, Kamal, Swoap, Steven J.
Publicado 2014

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

por Kaufman, Allegra, Abuqayyas, Lubna, Denney, William S., Tillman, Erik J., Rolph, Tim
Publicado 2020

Global transcriptional regulation of innate immunity by ATF-7 in C. elegans

por Fletcher, Marissa, Tillman, Erik J., Butty, Vincent L., Levine, Stuart S., Kim, Dennis H.
Publicado 2019

De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling

por Del Vecchio, Catherine A., Feng, Yuxiong, Sokol, Ethan S., Tillman, Erik J., Sanduja, Sandhya, Reinhardt, Ferenc, Gupta, Piyush B.
Publicado 2014

Generation of Affinity Purified Antibody Reagents for Specific Determination of Efruxifermin in Biological Matrices

por Kinne, Adam S, Abdeen, Sanofar J, Parmer, Elijah S, Thystrup, Jennifer A, Tillman, Erik J, Rolph, Timothy P, Bowsher, Ronald R
Publicado 2021

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

por Harrison, Stephen A., Ruane, Peter J., Freilich, Bradley, Neff, Guy, Patil, Rashmee, Behling, Cynthia, Hu, Chen, Shringarpure, Reshma, de Temple, Brittany, Fong, Erica, Tillman, Erik J., Rolph, Timothy, Cheng, Andrew, Yale, Kitty
Publicado 2022